CAS 1231732-19-6 | AVAC-003 : Avacopan

CAS 1231732-19-6 | AVAC-003 : Avacopan
(World's Largest Pharmaceutical Supplier)

  • CAS Number: 1231732-19-6
  • Stock: 999g
  • Assay: 0.00%

Abstract:

CAS 1231732-19-6 is a chemical compound with a molecular formula of C18H26ClN3O2S. It is a white crystalline powder that is used in the pharmaceutical industry for its anti-inflammatory properties. This article will explore the chemical properties and uses of CAS 1231732-19-6.


1. Chemical Properties:

CAS 1231732-19-6 has a melting point of 195-197°C and a boiling point of 564.4°C at 760 mmHg. It has a molecular weight of 381.94 g/mol and a density of 1.27 g/cm³. The compound is soluble in dimethyl sulfoxide and dimethylformamide, but slightly soluble in water. It is also stable under normal conditions of use and storage.


2. Uses:

CAS 1231732-19-6 is primarily used in the pharmaceutical industry as an anti-inflammatory drug. It works by inhibiting the production of prostaglandins, which are responsible for causing inflammation in the body. The compound has been found to be effective in treating a variety of inflammatory conditions such as rheumatoid arthritis, osteoarthritis, and psoriasis. It is also being researched for its potential use in treating other conditions such as cancer and Alzheimer's disease.


In addition to its anti-inflammatory properties, CAS 1231732-19-6 has also been found to have antimicrobial activity against a variety of bacteria and fungi. This makes it a potential candidate for use in the development of new antibiotics.


Conclusion:

CAS 1231732-19-6 is a white crystalline powder with anti-inflammatory and antimicrobial properties. It is primarily used in the pharmaceutical industry for its ability to treat inflammatory conditions such as rheumatoid arthritis and osteoarthritis. The compound is also being researched for its potential use in treating other conditions such as cancer and Alzheimer's disease. Its antimicrobial activity makes it a potential candidate for use in the development of new antibiotics.